Randomized Controlled Trials: Evidence Biased Psychiatry By David Healy, MD MRCPsych Introduction A new drug gets introduced to the market. It has been approved after stringent scrutiny by the FDA, which requires ever more convincing evidence that it works and that its safe. The new treatment will always cost more than the old treatments, but…

Read More

A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.

Read More

Debate Over Antidepressants – Letters NYT Mon, 11 Aug 2003 The New York Times published 5 letters re: “Debate Resumes on the Safety of Depression’s Wonder Drugs.” One letter from someone who experienced “a minor depressive episode” and was prescribed Celexa, one of the SSRI antidepressants. He describes experiencing “extreme, almost manic tendencies” during the…

Read More

References for THE IMPACT OF THE FDA MODERNIZATION ACT ON THE RECRUITMENT OF CHILDREN FOR RESEARCH Vera Hassner Sharav Published in ETHICAL HUMAN SCIENCES & SERVICES Summer 2003, vol. 5 pp. 83-108 Agency for Health Care Research & Quality. (1999). Treatment of attention-deficit/hyperactivity disorder: Summary, evidence Report / Technology assessment number 11. AHQR Publication No.…

Read More